|By Business Wire||
|August 5, 2014 03:20 PM EDT||
VuCOMP, leading developer of advanced computer vision systems for the detection of breast cancer, today applauded the introduction of national breast density notification legislation by the United States Senate. The bipartisan bill was introduced by Senator Dianne Feinstein (D-CA) and Senator Kelly Ayotte (R-NH). A similar bill was introduced in the House by Representatives Rosa DeLauro (D-CT) and Steve Israel (D-NY). All of the legislative activity follows a wave of breast density notification laws enacted by 19 states to date.
The Breast Density and Mammography Reporting Act would set a minimum federal standard, as designated by the Secretary of Health and Human Services (HHS), for notification of breast density status and would recommend women discuss with their doctors whether additional screening is necessary. The bill also directs HHS to study improved screening options for women with dense tissue.
Senator Feinstein said in a statement, “Early detection of breast cancer is key to survival, and women must be given every available resource to make informed health care decisions. By requiring that patients be informed if they have dense tissue, this bill allows women to make potentially lifesaving choices about their care.”
“We support a national standard on breast density reporting and applaud this important initiative by the US Senate,” said Jim Pike, President and CTO of VuCOMP. “This sheds light on the role of breast density in the detection and incidence of breast cancer, as well as the overall importance of being armed with the information one needs to make critical healthcare decisions.”
VuCOMP has responded to the need for standardization and automation of breast density measurement. In December 2013 the company received FDA approval for and released M-Vu Breast Density. M-Vu Breast Density is designed to improve the science of breast density measurement by using advanced computer algorithms to identify dense tissue in the breast that could be masking cancer.
About VuCOMP, Inc.
VuCOMP, Inc. leads the way in setting a new standard for CAD and automated breast density measurement. The company is dedicated exclusively to developing advanced cancer detecting technologies. VuCOMP’s engineering team has worked together since 1986, pioneering some of the world’s most advanced computer vision systems. For more information, please visit www.vucomp.com.